To evaluate the potential of ALT-TFs as a cancer biomarker for liquid biopsy analysis, we estimated the tumour fraction in cell-free DNA from glioblastoma patients and healthy controls using ichorCNA57, and compared them against the ALT-TF rates. This evidence concerns the gene TF and glioblastoma.